

Survey: DS3/22
month: August 2022
Participant-No: 6426202
date of issue: 06.08.22



Referenzinstitut für Bioanalytik

Labor Dr. Spranger
Lindberghstr. 9-13
85051 Ingolstadt



Survey directors

Prof. Dr. C. Knabbe
Prof. Dr. Dr. K.P. Kohse
Prof. Dr. M. Neumaier

Head of RfB

Dr. A. Kessler

Certificate

I. Screening (immunologic)

Correct findings were reported on the following:

- Amphetamine group
- Barbiturates
- Benzodiazepines
- Cannabinoids
- Cocain + metabolites
- Opiates

Bonn, 28. September 2022
Rev. 1

This certificate is according to the current version of the RiliBÄK valid until the end of February 2023.